StreetAlpha.app
Home › Stocks › ALEC

Alector, Inc. (ALEC)

Healthcare
$2.56
▼ −0.39%
LAST CLOSE · NOV 17

Alector develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It last closed at $2.56 on Nov 17, down 0.39% on the day. The average 12-month price target from 2 analysts is $5.50 (+114.8% from the last close), with a high of $8.00 and a low of $3.00. In the past 30 days there were 2 dark pool prints totaling $281K, the largest $175K.

AI Auto Pilots
Is ALEC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$173.5M
+151.2% vs a year ago
Net income
$41.4M
23.9% margin
EPS (diluted)
$0.36
Free cash flow
−$150.0M
−86.5% margin
Valuation
Market cap
$381.1M
148.9M shares
P/E
7.1
Price over 12 month EPS
Price to sales
2.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$75.5M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
$116.6M
Shares outstanding
148.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $207.1M$207.1MFY2021FY2022: $133.6M$133.6MFY2022FY2023: $97.1M$97.1MFY2023FY2024: $100.6M$100.6MFY2024FY2025: $21.0M$21.0MFY2025

From ALEC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Sell
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Sell
2firms
1 Buy0 Hold1 Sell
Only 2 firms rated ALEC in the past 90 days, not enough for a consensus
Average 12-month target
$5.50
▲ 114.8% upside

Based on 2 analysts who set a price target on ALEC in the past 90 days. The average target is $5.50, with a high of $8.00 and a low of $3.00, compared with the last close of $2.56.

Low $3.00Avg $5.50High $8.00
Blue marker: last close $2.56
Highest target$8.00
Average target$5.50
Lowest target$3.00
Latest rating changes
HC Wainwright & Co.Maintained
Oct 14Buy$8
Morgan StanleyMaintained
Oct 6Sell$3
DateFirmActionRatingPrice target
Oct 14HC Wainwright & Co.MaintainedBuy$8
Oct 6Morgan StanleyMaintainedSell$3
Loading…

Technical Analysis

ALEC · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 13% above its 20 day and 19% above its 50 day average. It is 20% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62), near overbought. The nearest support is the Pivot S1 at $2.50, and the nearest resistance the Pivot R1 at $2.61.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 8.2%/day
Key levels
$2.8452 week high+10.9%
$2.73Swing high (Oct 5)+6.6%
$2.61Pivot R1+2.0%
$2.56Pivot+0.0%
$2.56Last close
$2.50Pivot S1−2.3%
$2.2420 day average−12.5%
$2.22Swing low (Sep 1)−13.3%
$2.0750 day average−19.1%
$2.06200 day average−19.5%
$1.99100 day average−22.3%
$1.0952 week low−57.4%
Indicators
RSI (14)62.34Strong, overbought above 70Neutral
MACD0.15Above its signal lineBullish
Stochastic67.7Middle of its rangeNeutral
ADX (14)28.0Trending up
Williams %R-34.4Oversold below −80, overbought above −20Neutral
CCI (20)101.3Oversold below −100, overbought above 100Overbought
Rate of change+24.9%Change over 10 sessionsBullish
ATR (14)$0.21Typical daily range, 8.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ALEC

What happened before

See how ALEC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALEC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALEC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALEC in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$281K
Largest print
$175K
Loading…

ALEC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼52 buying vs 74 selling
  • ▼Held by funds -0.6 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding137141−2.8%
In funds' top 10330.0%
Held by funds63.8%64.4%−0.6 pts
New / increased14 / 3814 / 59−28.8%
Reduced / sold out55 / 1935 / 9+68.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALEC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALEC is in one of them and how their past ALEC trades turned out.

ALEC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALEC in an article yet. Here's the latest on the wider market.

About Alector

Alector is a biotechnology company that develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its drug candidates aim to remove harmful proteins, replace missing ones, or restore normal cell function. The company also builds a proprietary technology designed to help drugs reach the brain, and it partners with drugmakers such as GSK on some programs. Based in South San Francisco, California, Alector is still testing its candidates in clinical studies.

Headquarters
South San Francisco, CA
Founded
2013